Astrocytoma (excluding glioblastoma)
Therapeutic area
Neurology
Rare disease
No
- Definition
- A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Astrocytoma (excluding glioblastoma)
- Therapeutic area
- Neurology
- astrocytoma (excluding glioblastoma)
- astrocytoma
- Severity
- Moderate
- Neurology
- Oncology
- MONDO ID
- MONDO:0019781
- Parent condition
- MONDO:0021636
Related records
Broader conditions (12)
- Astrocytic tumor
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Glioma
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Nervous system disorder
- Nervous system neoplasm
- Neuroepithelial neoplasm
Narrower conditions (37)
- Adult brainstem astrocytoma
- Anaplastic astrocytoma
- Astrocytoma, IDH-mutant, grade 2
- Astrocytoma, IDH-mutant, grade 3
- Astrocytoma, IDH-mutant, grade 4
- Brain astrocytoma
- Brain stem astrocytic neoplasm
- Cauda equina intradural extramedullary astrocytoma
- Cerebellar astrocytoma
- Cerebellar pilocytic astrocytoma
- Cerebral astrocytoma
- Childhood brainstem astrocytoma
- Childhood cerebellar astrocytic neoplasm
- Childhood cerebral astrocytoma
- Childhood optic tract astrocytoma
- Childhood pilocytic astrocytoma
- Diencephalic astrocytomas
- Diffuse astrocytoma
- Diffuse astrocytoma, MYB- or MYBL1-altered
- Fibrillary astrocytoma
Trials (672)
- (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas
- 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
- 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
- 3D Prediction of Patient-Specific Response
- 3T MRI Biomarkers of Glioma Treatment Response
- 5-ALA in Recurrent Glioma
- A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas
- A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
- A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
- A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
- A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
- A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
- A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
- A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
- A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
- A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
- A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
- A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
- A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
- A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
Approved drugs (3)
- Carmustine
- Everolimus
- Vorasidenib
Drugs in development (38)
- Antineoplaston A10 Phase 2
- Atezolizumab Phase 2
- Bevacizumab Phase 2
- BMX-001 Phase 2
- Cabozantinib S-malate Phase 2
- Carboplatin Phase 3
- Chlorotoxin Phase 2
- Cintredekin besudotox Phase 1
- Denifanstat Phase 2
- Disufenton sodium Phase 1
- Doxorubicin Phase 2
- Erlotinib Phase 1
- Etoposide Phase 2
- Guanine Phase 2
- Hiltonol Phase 1
- Hydroxyurea Phase 3
- Icapamespib Phase 1
- Imatinib mesylate Phase 3
- Influenza virus vaccine Phase 2
- Irinotecan Phase 2